Cargando…
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1
Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them. Virotherapy is a flexible tool that can be used to stimulate and/or recruit different immune populations. T-cell enabling vi...
Autores principales: | Cervera-Carrascon, Victor, Quixabeira, Dafne C. A., Santos, Joao M., Havunen, Riikka, Milenova, Ioanna, Verhoeff, Jan, Heiniö, Camilla, Zafar, Sadia, Garcia-Vallejo, Juan J., van Beusechem, Victor W., de Gruijl, Tanja D., Kalervo, Aino, Sorsa, Suvi, Kanerva, Anna, Hemminki, Akseli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343222/ https://www.ncbi.nlm.nih.gov/pubmed/34367166 http://dx.doi.org/10.3389/fimmu.2021.706517 |
Ejemplares similares
-
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
por: Quixabeira, Dafne C. A., et al.
Publicado: (2022) -
TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
por: Heiniö, Camilla, et al.
Publicado: (2020) -
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022) -
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020) -
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
por: Santos, Joao, et al.
Publicado: (2021)